Preservación de la fertilidad en el tumor ovárico borderline

IF 0.1 Q4 OBSTETRICS & GYNECOLOGY

Clinica e Investigacion en Ginecologia y Obstetricia Pub Date : 2024-01-04 DOI:10.1016/j.gine.2023.100933

S. Peón Muñoz

{"title":"Preservación de la fertilidad en el tumor ovárico borderline","authors":"S. Peón Muñoz","doi":"10.1016/j.gine.2023.100933","DOIUrl":null,"url":null,"abstract":"<div>Borderline ovarian tumors (BOTs) are defined as “tumors of low malignant potential”. These are epithelial neoplasms that debut mainly in young women, and are usually diagnosed in the initial stages of the disease.The main key to its treatment is surgery, thus compromising the fertility of the patient who has not fulfilled her reproductive desire. In general, the choice of surgery for BOTs should consider the characteristics of the tumor, the patient's fertility desires, and the extent of the disease. The decisions made in this regard must be individualized and advised by a multidisciplinary team.Fertility preservation (FP) plays an important role in the management of these patients, and there are different strategies to improve and maintain their quality of life.Reproductive counseling should be an integral part of clinical management, with risks and benefits carefully considered.Given its low incidence, there is little literature on the matter, requiring well-designed prospective studies to address specific fertility problems both in the initial diagnosis and in recurrences of patients with BOTs.</div>","PeriodicalId":41294,"journal":{"name":"Clinica e Investigacion en Ginecologia y Obstetricia","volume":"51 2","pages":"Article 100933"},"PeriodicalIF":0.1000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Ginecologia y Obstetricia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210573X2300103X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Borderline ovarian tumors (BOTs) are defined as “tumors of low malignant potential”. These are epithelial neoplasms that debut mainly in young women, and are usually diagnosed in the initial stages of the disease.

The main key to its treatment is surgery, thus compromising the fertility of the patient who has not fulfilled her reproductive desire. In general, the choice of surgery for BOTs should consider the characteristics of the tumor, the patient's fertility desires, and the extent of the disease. The decisions made in this regard must be individualized and advised by a multidisciplinary team.

Fertility preservation (FP) plays an important role in the management of these patients, and there are different strategies to improve and maintain their quality of life.

Reproductive counseling should be an integral part of clinical management, with risks and benefits carefully considered.

Given its low incidence, there is little literature on the matter, requiring well-designed prospective studies to address specific fertility problems both in the initial diagnosis and in recurrences of patients with BOTs.

查看原文本刊更多论文

边缘性卵巢肿瘤的生育力保护

边缘性卵巢肿瘤（BOTs）被定义为 "恶性程度较低的肿瘤"。这些肿瘤是上皮性肿瘤，主要在年轻女性中首发，通常在疾病的初期阶段被诊断出来。治疗的主要关键是手术，因此会影响尚未实现生育愿望的患者的生育能力。一般来说，BOT 手术的选择应考虑肿瘤的特点、患者的生育愿望和疾病的程度。生育力保护（FP）在这些患者的治疗中扮演着重要的角色，有不同的策略来改善和维持他们的生活质量，生殖咨询应该是临床治疗中不可或缺的一部分，并仔细考虑风险和益处。鉴于其发病率较低，这方面的文献很少，因此需要进行精心设计的前瞻性研究，以解决 BOTs 患者初诊和复发时的具体生育问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica e Investigacion en Ginecologia y Obstetricia OBSTETRICS & GYNECOLOGY-

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Una excelente publicación para mantenerse al día en los temas de máximo interés de la ginecología de vanguardia. Resulta idónea tanto para el especialista en ginecología, como en obstetricia o en pediatría, y está presente en los más prestigiosos índices de referencia en medicina.